News

COVIDsmart Study Launched to Understand Pandemic’s Impact on Individuals and Communities Across VA

COVIDsmart, a digital health study designed to examine the many impacts of COVID-19 on individuals and their communities launched today, with an open call for participation. The study welcomes participants from all walks of life across Virginia to share information on how the pandemic has affected their lives, even if they have not had COVID-19.

The initiative is sponsored by EVMS-Sentara Healthcare Analytics and Delivery Science Institute (HADSI), George Mason University (Mason), and health technology company Vibrent Health who are leading the initiative to gather information to help participants, researchers and public health entities better understand and address the impacts of the pandemic and future health crises.

The study asks participants questions related to the pandemic and its impact on daily life, particularly its impact on financial, mental, and physical well-being such as, “Over the past 30 days, has your consumption of alcohol increased, decreased, or remained the same?” and, “How likely are you to want to receive COVID-19 vaccination?”

“Minimizing the impact of future pandemics on you and your community requires a deeper understanding of how COVID has affected you – even if you or those you know have not had COVID-19. Everyone can make a difference during this pandemic by contributing to research. Sharing important information not just about your health but how you’ve been impacted emotionally, socially, economically, and other ways will help inform decisions that benefit all of us,” said Sunita Dodani, MBBS, PhD, Professor of Internal Medicine at Eastern Virginia Medical School (EVMS), Director of HADSI and member of the Federation of American Scientists’ COVID-19 Rapid Response Task Force.

COVIDsmart differs from other COVID-19 studies because it will give back aggregate de-identified study data to participants, so they can see how the pandemic has impacted them and their community. The study will also provide participants with resources and information — such as health and safety recommendations from governmental organizations — to help them protect themselves and their communities from COVID-19 infection.

“As we look to the future, policy makers will require a deep understanding of the multi-faceted impact of the pandemic on people and on our public health infrastructure,” said Virginia Secretary of Health and Human Resources, Daniel Carey, MD, MHCM. “Studies like this one can help us to fully assess the effects of COVID-19 and chart a path forward.”
To represent the full picture of COVID’s impact, the study aims to recruit individuals who are diverse in age, gender, sexuality, ethnicity, race, and culture to reflect Virginia’s diversity and to include groups historically underrepresented in biomedical research.

“Diversity in COVID-19 research is essential for the public health decision-makers to accurately address disparities, such as infection rates, access to testing, health care, unemployment and availability of support services,” said Amira Roess, an epidemiologist and professor in the Department of Global and Community Health at George Mason University. “Our goal with COVIDsmart is to gain and share knowledge that will aid public health organizations in giving guidance and dedicating resources that will help minimize the impacts of the COVID-19 pandemic and any other future health crises among individuals, their families and communities.”

COVIDsmart uses a privacy-protecting, secure platform, provided by Vibrent Health, developers of the technology platform for NIH’s All of Us Research Program. The platform, which was built to collect many types of data from diverse populations, can expand to accommodate broad data sources such as wearables and biospecimens, depending on the needs of the longitudinal study. COVIDsmart’s anonymized results will be made available to researchers and public health policy officials to help guide them in identifying at-risk communities that are disproportionately affected by COVID-19. These insights can help direct resources and services where they are most needed during the coronavirus pandemic and any potential future health crisis.

“One of the valuable features of COVIDsmart is that participants can engage in the study virtually and remotely,” said Vibrent Health CEO Praduman “PJ” Jain. “Technology allows us to reach people wherever they are, so that everyone can have a voice and make an impact in this important health research.”

The study is open to anyone at least 18 years old living in Virginia and will gather information about participants’ experiences through the course of the pandemic. The study consists of easy-to-understand online surveys. As an incentive to participants, COVIDsmart offers gift card drawings for those who stay active in the study.

To learn more about COVIDsmart, visit: www.covidsmartstudy.org

Recent News

10/11/2024

FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved ItovebiTM (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant, for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast

10/10/2024

RIVANNA initiates multi-site first-in-human study for Accuro XV musculoskeletal imaging system

RIVANNA®, developers of imaging-based medical solutions, has announced the launch of the first multi-site study employing the Accuro® XV musculoskeletal imaging system. This milestone follows a $30.5 million funding option executed in 2023 by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S.

10/09/2024

LifeNet Health’s Rapid Growth Continues with Acquisition of State-of-the-Art Virginia Beach Research Laboratory

A company that is a global leader in regenerative medicine has acquired a cutting-edge research laboratory in Virginia Beach. LifeNet Health will use the laboratory as a center of excellence for groundbreaking liver disease research and sports medicine applications. The dual function will provide better health solutions for a growing number of patients. Situated near